Chain delivers petition for Anvisa to analyze CoronaVac’s emergency request in three days – Prime Time Zone


According to the party, unequal treatment is occurring in the authorization process for the application of immunizers, since Fiocruz was not asked for the same information required from Butantan.

ADRIANA TOFFETTI / A7 PRESS / ESTADÃO CONTENT – 12/12/2020Coronavac is produced by Instituto Butantan in partnership with Chinese pharmaceutical company Sinovac

A Sustainability Network delivered to Ricardo Lewandowski, Minister of Federal Supreme Court (STF), petition for the National Health Surveillance Agency (Anvisa) review CoronaVac’s emergency use request in three days, vaccine manufactured by the Butantan Institute in partnership with the Chinese pharmaceutical company Sinovac. According to the document, unequal treatment by the agency would be occurring in the authorization process for the application of immunizers against Covid-19. In comparison with the vaccine of Oxford University / Astrazeneca, it is argued that there was a quicker appraisal of the order delivered by Fiocruz. In addition, it is highlighted that Fiocruz was not asked for the same information required from Butantan.

For the Network, the Federal Government “has been showing an apparent ideological predilection over scientifically based decisions”, since CoronaVac was developed by a Chinese company in partnership with the government of the State of São Paulo, whose current mandate is to João Doria (PSDB), one of the President of the Republic’s main political rivals, Jair Bolsonaro. The party then states that the president would be interfering in the evaluation process of Anvisa, which has imposed ‘unnecessary and unused bureaucratic locks on the similar immunizer to delay approval’ of the vaccine.

It is highlighted in the document that on the date of submission of the request for emergency use of CoronaVac in Brazil, the application of the vaccine had already been authorized by the Chinese regulatory agency. Remember in the petition that China is among the countries mentioned in Law No. 13,979 / 2020, which makes the authorization by Anvisa peers that have international recognition as a precedent for emergency immunization approval. In addition, it is argued that Indonesia, where the broader immunization efficacy test was carried out, has also authorized the use of the vaccine.

The party defends, then, that the vaccine already has proven effectiveness and that it is already ready for application in the population. It is also emphasized that more than 200 thousand lives have already been lost during the pandemic and it is defended that the start of immunization is urgent to prevent more deaths in the country by the disease. “Most certainly, all of the more than 200,000 victims of Covid-19 in Brazil they would love to have had the chance to be immunized with any effective and safe vaccine available, without any prejudice of a political nature or nationality ”, writes the party.

* With information from Estadão Content